These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23640893)

  • 1. Interleukin-2 inhibits HIV-1 replication in some human T cell lymphotrophic virus-1-infected cell lines via the induction and incorporation of APOBEC3G into the virion.
    Oguariri RM; Dai L; Adelsberger JW; Rupert A; Stevens R; Yang J; Huang D; Lempicki RA; Zhou M; Baseler MW; Lane HC; Imamichi T
    J Biol Chem; 2013 Jun; 288(24):17812-22. PubMed ID: 23640893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functional conserved intronic G run in HIV-1 intron 3 is critical to counteract APOBEC3G-mediated host restriction.
    Widera M; Hillebrand F; Erkelenz S; Vasudevan AA; Münk C; Schaal H
    Retrovirology; 2014 Aug; 11():72. PubMed ID: 25169827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.
    Browne EP; Allers C; Landau NR
    Virology; 2009 May; 387(2):313-21. PubMed ID: 19304304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein 70 inhibits HIV-1 Vif-mediated ubiquitination and degradation of APOBEC3G.
    Sugiyama R; Nishitsuji H; Furukawa A; Katahira M; Habu Y; Takeuchi H; Ryo A; Takaku H
    J Biol Chem; 2011 Mar; 286(12):10051-7. PubMed ID: 21228271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.
    Hosseini I; Mac Gabhann F
    PLoS Comput Biol; 2012 Feb; 8(2):e1002371. PubMed ID: 22346743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
    Martin KL; Johnson M; D'Aquila RT
    J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
    Ao Z; Yu Z; Wang L; Zheng Y; Yao X
    PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
    Feng Y; Love RP; Chelico L
    J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-IL6 (C/EBPbeta) induces HIV-1 replication by inhibiting cytidine deaminase APOBEC3G.
    Kinoshita SM; Taguchi S
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15022-7. PubMed ID: 18809921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study.
    Hosseini I; Mac Gabhann F
    PLoS One; 2013; 8(5):e63984. PubMed ID: 23724012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells.
    Vetter ML; D'Aquila RT
    J Virol; 2009 Sep; 83(17):8646-54. PubMed ID: 19535442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
    Fan B; Cen S; Jiang JD
    Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.
    Vetter ML; Johnson ME; Antons AK; Unutmaz D; D'Aquila RT
    PLoS Pathog; 2009 Feb; 5(2):e1000292. PubMed ID: 19197360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner.
    Vallanti G; Lupo R; Federico M; Mavilio F; Bovolenta C
    Mol Ther; 2005 Oct; 12(4):697-706. PubMed ID: 16039909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.